Vanguard Capital Management
INAB icon

Vanguard Capital Management’s IN8bio INAB Stock Holding History

Vanguard Capital Management’s Portfolio INAB Stock Details INAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$127K Hold
88,865
– – ﹤0.01% 3855
2026
Q1 		$132K Buy
+88,865
New +$172K ﹤0.01% 3840

Other funds holding INAB

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

Vanguard Capital Management's INAB Position: Q2 2026 in Review

Vanguard Capital Management held its IN8bio (INAB) position steady in Q2 2026 at 88,865 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #3855.

Vanguard Capital Management first reported a position in INAB in Q1 2026 and has held it in 2 quarters since. The position peaked at $132K in Q1 2026. 21 funds tracked by Wall St. Rank hold INAB as of Q2 2026.

  • Vanguard Capital Management held 88,865 shares of IN8bio worth $127K as of Q2 2026.
  • Vanguard Capital Management left its IN8bio share count unchanged in Q2 2026.
  • IN8bio made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3855 holding.
  • Vanguard Capital Management first reported a position in IN8bio in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's IN8bio position peaked at $132K in Q1 2026.
  • 21 funds tracked by Wall St. Rank held IN8bio as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.